Topoisomerase-1 gene copy aberrations are frequent in patients with breast cancer

International Journal of Cancer

Volumn 137, Issue 8, 2015, Pages 2000-2006

  Kümler, Iben ^a   Balslev, Eva ^a   Poulsen, Tim S ^a   Nielsen, Signe Lykke ^b   Rømer, Maria Unni ^a   Christensen, Ib Jarle ^c   Høgdall, Estrid ^a   Moreira, José ^b   Nielsen, Dorte L ^a   Brünner, Nils ^b   Stenvang, Jan ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

breast cancer; fluorescence in situ hybridization; irinotecan; topoisomerase 1 gene

Indexed keywords

DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; TOP1 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; COHORT ANALYSIS; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE DOSAGE; HUMAN; PREVALENCE; PRIORITY JOURNAL; PROTEIN TARGETING; RETROSPECTIVE STUDY; TOP1 GENE; TREATMENT RESPONSE; VALIDATION PROCESS; BREAST TUMOR; CENTROMERE; CHROMOSOME 20; ENZYMOLOGY; FEMALE; GENETICS; METASTASIS; PATHOLOGY;

BREAST NEOPLASMS; CENTROMERE; CHROMOSOMES, HUMAN, PAIR 20; COHORT STUDIES; DNA TOPOISOMERASES, TYPE I; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; NEOPLASM METASTASIS;

EID: 84938954955     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29556     Document Type: Article

References (26)

1. Fuchs C, Mitchell EP, Hoff PM,. Irinotecan in the treatment of colorectal cancer. Cancer Treat Rev 2006; 32: 491-503.
2. Kumler I, Brunner N, Stenvang J, et al., A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer. Breast Cancer Res Treat 2013; 138: 347-58.
3. Awada A, Garcia AA, Chan S, et al., Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study. Lancet Oncol 2013; 14: 1216-25.
4. Horisberger K, Erben P, Muessle B, et al., Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer. Anticancer Drugs 2009; 20: 519-24.
5. Kostopoulos I, Karavasilis V, Karina M, et al., Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy. BMC Cancer 2009; 9: 339
6. Braun MS, Richman SD, Quirke P, et al., Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 2008; 26: 2690-8.
7. Paradiso A, Xu J, Mangia A, et al., Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients. Int J Cancer 2004; 111: 252-8.
8. Vallbohmer D, Iqbal S, Yang DY, et al., Molecular determinants of irinotecan efficacy. Int J Cancer 2006; 119: 2435-42.
9. Miao ZH, Player A, Shankavaram U, et al., Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses. Cancer Res 2007; 67: 8752-61.
10. Lynch BJ, Bronstein IB, Holden JA,. Elevations of DNA topoisomerase I in invasive carcinoma of the breast. Breast J 2001; 7: 176-80.
11. McLeod HL, Keith WN,. Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity. Br J Cancer 1996; 74: 508-12.
12. Maughan TS, Meade AM, Adams RA, et al., A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC focus3): a model for randomised controlled trials in the era of personalised medicine? Br J Cancer 2014; 110: 2178-86.
13. xRomer MU, Jensen NF, Nielsen SL, et al., top1 gene copy numbers in colorectal cancer samples and cell lines and their association to in vitro drug sensitivity. Scand J Gastroenterol 2012; 47: 68-79.
14. Smith DH, Christensen IJ, Jensen NF, et al., Mechanisms of topoisomerase I (top1) gene copy number increase in a stage III colorectal cancer patient cohort. PLoS One 2013; 8: e60613
15. Zhao S, Stodolsky M., Bacterial artificial chromosomesed. Totowa, N.J.: Humana Press, 2004.
16. Moisan F, Longy M, Robert J, et al., Identification of gene polymorphisms of human DNA topoisomerase I in the national cancer institute panel of human tumour cell lines. Br J Cancer 2006; 95: 906-13.
17. Tanner MM, Tirkkonen M, Kallioniemi A, et al., Independent amplification and frequent co-amplification of three nonsyntenic regions on the long arm of chromosome 20 in human breast cancer. Cancer Res 1996; 56: 3441-5.
18. Cerami E, Gao J, Dogrusoz U, et al., The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2: 401-4.
19. Gao J, Aksoy BA, Dogrusoz U, et al., Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6: pl1
20. Beroukhim R, Getz G, Nghiemphu L, et al., Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci USA 2007; 104: 20007-12.
21. Reinhold WC, Mergny JL, Liu H, et al., Exon array analyses across the NCI-60 reveal potential regulation of top1 by transcription pausing at guanosine quartets in the first intron. Cancer Res 2010; 70: 2191-203.
22. Yu J, Miller R, Zhang W, et al., Copy-number analysis of topoisomerase and thymidylate synthase genes in frozen and FFPE DNAs of colorectal cancers. Pharmacogenomics 2008; 9: 1459-66.
23. Husain I, Mohler JL, Seigler HF, et al., Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res 1994; 54: 539-46.
24. Hanna WM, Ruschoff J, Bilous M, et al., her2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Mod Pathol 2014; 27: 4-18.
25. Jameson GS, Petricoin EF, Sachdev J, et al., A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer. Breast Cancer Res Treat 2014; 147: 579-88.
26. Nielsen DL, Brunner N,. Etirinotecan pegol: an option for late-stage breast cancer? Lancet Oncol 2013; 14: 1149-51.